Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

901 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular Characterization of Whole-Genome SARS-CoV-2 from the First Suspected Cases of the XE Variant in the Lazio Region, Italy.
Rueca M, Giombini E, Gramigna G, Gruber CEM, Fabeni L, Corpolongo A, Mazzotta V, Corso L, Butera O, Valli MB, Carletti F, Pignalosa S, Vairo F, Nicastri E, Antinori A, Girardi E, Vaia F, Maggi F, Sars CoV-Lazio Surveillance Study Group. Rueca M, et al. Among authors: antinori a. Diagnostics (Basel). 2022 Sep 14;12(9):2219. doi: 10.3390/diagnostics12092219. Diagnostics (Basel). 2022. PMID: 36140622 Free PMC article.
Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy.
Giancola ML, Lorenzini P, Balestra P, Larussa D, Baldini F, Corpolongo A, Narciso P, Bellagamba R, Tozzi V, Antinori A. Giancola ML, et al. Among authors: antinori a. J Acquir Immune Defic Syndr. 2006 Mar;41(3):332-7. doi: 10.1097/01.qai.0000197077.64021.07. J Acquir Immune Defic Syndr. 2006. PMID: 16540934
Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.
Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, Vlassi C, Giulianelli M, Galgani S, Antinori A, Narciso P. Tozzi V, et al. Among authors: antinori a. J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):174-82. doi: 10.1097/QAI.0b013e318042e1ee. J Acquir Immune Defic Syndr. 2007. PMID: 17356465
HIV-Infected Late Presenter Patients.
D'Arminio Monforte A, Antinori A, Girardi E, Ceccherini-Silberstein F, Marchetti G, Sabin CA, Montaner JS. D'Arminio Monforte A, et al. Among authors: antinori a. AIDS Res Treat. 2012;2012:902679. doi: 10.1155/2012/902679. Epub 2011 Nov 29. AIDS Res Treat. 2012. PMID: 22191018 Free PMC article. No abstract available.
Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis.
Girardi E, Scognamiglio P, Angeletti C, Gori A, Buonfrate D, Arlotti M, Mazzarello G, Castagna A, Andreoni M, d'Arminio Monforte A, Antinori A, Ippolito G; I.Co.Na Foundation Study. Girardi E, et al. Among authors: antinori a. BMC Health Serv Res. 2012 Feb 15;12:38. doi: 10.1186/1472-6963-12-38. BMC Health Serv Res. 2012. PMID: 22336471 Free PMC article.
Impact of pre-therapy viral load on virological response to modern first-line HAART.
Santoro MM, Armenia D, Alteri C, Flandre P, Calcagno A, Santoro M, Gori C, Fabeni L, Bellagamba R, Borghi V, Forbici F, Latini A, Palamara G, Libertone R, Tozzi V, Boumis E, Tommasi C, Pinnetti C, Ammassari A, Nicastri E, Buonomini A, Svicher V, Andreoni M, Narciso P, Mussini C, Antinori A, Ceccherini-Silberstein F, Di Perri G, Perno CF. Santoro MM, et al. Among authors: antinori a. Antivir Ther. 2013;18(7):867-76. doi: 10.3851/IMP2531. Epub 2013 Jan 23. Antivir Ther. 2013. PMID: 23343501 Free article.
901 results